Current Neurology and Neuroscience Reports

, 11:484

First online:

Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine

  • Manuel ComabellaAffiliated withCentre d’Esclerosi Múltiple de Catalunya, CEM-Cat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron
  • , Koen VandenbroeckAffiliated withNeurogenomiks Laboratory, Department of Neuroscience, University of the Basque Country UPV/EHUIKERBASQUE, Basque Foundation for ScienceNeurogenomiks, Dpto de Neurociencias, Universidad del País Vasco UPV/EHU, Parque Tecnológico de Bizkaia Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Notwithstanding the availability of disease-modifying treatments including interferon-β, glatiramer acetate, and natalizumab, a considerable proportion of multiple sclerosis (MS) patients experience continued progression of disease, clinical relapses, disease activity on MRI, and adverse effects. Application of gene expression, proteomic or genomic approaches is universally accepted as a suitable strategy toward the identification of biomarkers with predictive value for beneficial/poor clinical response to therapy and treatment risks. This review focuses on recent progress in research on the pharmacogenomics of disease-modifying therapies for MS. Although MS drug response biomarkers are not yet routinely implemented in the clinic, the diversity of reported, promising molecular markers is rapidly increasing. Even though most of these markers await further validation, given time, this research is likely to empower neurologists with an enhanced armamentarium to facilitate rational decisions on therapy and patient management.


Multiple sclerosis Interferon-β Glatiramer acetate Natalizumab Single nucleotide polymorphism Biomarker Genomic Proteomic Drug response Pharmacogenomics Individualized medicine